Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.
Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.
Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback